EFFECT OF DRUGS ON COLONIC EICOSANOID ACCUMULATION IN ACTIVE ULCERATIVE-COLITIS

被引:32
作者
ELIAKIM, R [1 ]
KARMELI, F [1 ]
CHOREV, M [1 ]
OKON, E [1 ]
RACHMILEWITZ, D [1 ]
机构
[1] HEBREW UNIV JERUSALEM, HADASSAH MED SCH, IL-91010 JERUSALEM, ISRAEL
关键词
ACETYL 5-AMINOSALICYLIC ACID; 4-AMINOSALICYLIC ACID; 5-AMINOSALICYLIC ACID; AZATHIOPRINE; CHLOROQUINE; CYCLOSPORINE; KETOTIFEN; METHOTREXATE; ULCERATIVE COLITIS;
D O I
10.3109/00365529209000172
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The effect of immunosuppressive drugs, 4-aminosalicylic acid (4-ASA), acetyl 5-aminosalicylic acid (5-ASA), and ketotifen on human colonic eicosanoid accumulation was evaluated in view of enhanced accumulation in patients with active ulcerative colitis. Azathioprine (100 mug/ml), cyclosporin (100 mug/ml), and methotrexate (100 mug/ml) significantly inhibited, by 25-35%, prostaglandin E2 (PGE2) accumulation by organ-cultured colonic mucosa of ulcerative colitis patients. Methotrexate was the only immunosuppressive drug that inhibited leukotriene B4 (LTB4) accumulation (50%), whereas azathioprine inhibited the accumulation of leukotriene C4 (LTC4) (25%). 5-ASA and its metabolite, acetyl 5-ASA, inhibited by 20-70% PGE2, LTB4, and LTC4 accumulation in the culture, supporting the contention that acetyl 5-ASA is as active as 5-ASA in these respects. 4-ASA had no effect on any of the eicosanoids. Ketotifen, a mast cell stabilizer, significantly inhibited the accumulation of PGE2, LTB4, and LTC4 by 33-60%. These results suggest a potential, new, unrecognized mode by which the immunomodulators induce part of their therapeutic effects in inflammatory bowel disease and support the contention that acetyl 5-ASA is as active as 5-ASA. The results obtained also indicate that ketotifen, used effectively in the prevention of bronchial asthma, inhibits the accumulation of colonic eicosanoids and, thus, may be of value in the treatment of inflammatory bowel disease.
引用
收藏
页码:968 / 972
页数:5
相关论文
共 48 条
[1]   COLONIC N-ACETYLATION OF 5-AMINOSALICYLIC ACID IN INFLAMMATORY BOWEL-DISEASE [J].
ALLGAYER, H ;
AHNFELT, NO ;
KRUIS, W ;
KLOTZ, U ;
FRANKHOLMBERG, K ;
SODERBERG, HNA ;
PAUMGARTNER, G .
GASTROENTEROLOGY, 1989, 97 (01) :38-41
[2]   RADIOIMMUNOLOGICAL ASSAY OF PROSTAGLANDIN SYNTHETASE-ACTIVITY [J].
BAUMINGER, S ;
ZOR, U ;
LINDNER, HR .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 1973, 4 (03) :313-324
[3]   EFFECT OF METHOTREXATE ON THE INTESTINAL-MUCOSA OF PGE2-TREATED RATS [J].
BERNARD, A ;
DANDRIFOSSE, G ;
ROMAIN, N ;
FORGET, P .
LIFE SCIENCES, 1989, 45 (26) :2591-2603
[4]   A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL OF CYCLOSPORINE THERAPY IN ACTIVE CHRONIC CROHNS-DISEASE [J].
BRYNSKOV, J ;
FREUND, L ;
RASMUSSEN, SN ;
LAURITSEN, K ;
DEMUCKADELL, OS ;
WILLIAMS, N ;
MACDONALD, AS ;
TANTON, R ;
MOLINA, F ;
CAMPANINI, MC ;
BIANCHI, P ;
RANZI, T ;
DIPALO, FQ ;
MALCHOWMOLLER, A ;
THOMSEN, OO ;
TAGEJENSEN, U ;
BINDER, V ;
RIIS, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (13) :845-850
[5]   CONTROLLED TRIAL OF DISODIUM-CROMOGLYCATE IN CHRONIC PERSISTENT ULCERATIVE-COLITIS [J].
BUCKELL, NA ;
GOULD, SR ;
DAY, DW ;
LENNARDJONES, JE ;
EDWARDS, AM .
GUT, 1978, 19 (12) :1140-1143
[6]  
DRONFIELD MW, 1967, GUT, V19, P1136
[7]   ROLE OF PLATELET-ACTIVATING FACTOR IN ULCERATIVE-COLITIS - ENHANCED PRODUCTION DURING ACTIVE DISEASE AND INHIBITION BY SULFASALAZINE AND PREDNISOLONE [J].
ELIAKIM, R ;
KARMELI, F ;
RAZIN, E ;
RACHMILEWITZ, D .
GASTROENTEROLOGY, 1988, 95 (05) :1167-1172
[8]  
ELIAKIM R, IN PRESS GUT
[9]  
GOULD SR, 1977, LANCET, V2, P98
[10]   COMPARATIVE TRIAL OF SODIUM CROMOGLYCATE ENEMAS WITH PREDNISOLONE ENEMAS IN THE TREATMENT OF ULCERATIVE-COLITIS [J].
GRACE, RH ;
GENT, AE ;
HELLIER, MD .
GUT, 1987, 28 (01) :88-92